BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

Not for distribution to U.S. newswire services or for dissemination in the United States.

VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / BioNxt Solutions Inc. (CSE:BNXT)(FSE:4XT) (the "Company" or "BioNxt") is pleased to announce a non-brokered private placement of units of the Company ("Units") at a price of $0.33 per Unit, for maximum aggregate gross proceeds of up to approximately $2,000,000 (the "Offering") pursuant to the Listed Issuer Financing ("LIFE") exemption available under Part 5A of National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"). Pursuant to the LIFE Offering, the Company will issue up to a maximum of 6,060,606 Units at a price of $0.33 per Unit for maximum gross proceeds of up to approximately $2,000,000. There is no minimum Offering. There is an offering document relating to the Offering that can be accessed under the Company's profile at www.sedarplus.ca and at www.bionxt.com. Prospective investors should read this offering document before making an investment decision. The securities offered under the LIFE Offering will not be subject to a hold period in accordance with applicable Canadian securities laws.

Each Unit will be comprised of one common share in the capital of the Company (a "Share") and one Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to acquire one additional Share (a "Warrant Share") at a price of $0.50 per Warrant Share until the date that is twenty-four (24) months from the closing date of the LIFE Offering.

In connection with the Offering, the Company will pay finder's fees of up to 6.0% of the gross proceeds raised by the Company from the sale of Units to subscribers directly introduced to the Company by eligible finders. In addition, the Company will issue to eligible finders non-transferable finder's warrants (each, a "Finder's Warrant") of up to 6.0% of the number of Units sold in the Offering. Each Finder's Warrant will entitle the holder to purchase one Share at an exercise price of $0.50 for a period of twenty-four (24) months from the date of issuance.

The Offering is expected to close before July 27, 2026.

The Company intends to use the proceeds raised from the Offering for conducting its European research and development and operations and for working capital and general corporate purposes.

Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including that of the Canadian Securities Exchange (the "CSE"). The Company may, at its discretion, elect to close the Offering sooner and/or in one or more tranches.

Schreibe Deinen Kommentar